359 related articles for article (PubMed ID: 23678073)
61. Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study.
Kim SH; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Han DJ
Infect Chemother; 2015 Jun; 47(2):105-10. PubMed ID: 26157588
[TBL] [Abstract][Full Text] [Related]
62. Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection.
Schachtner T; Stein M; Reinke P
Transpl Int; 2016 Dec; 29(12):1296-1306. PubMed ID: 27638250
[TBL] [Abstract][Full Text] [Related]
63. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation.
Páez-Vega A; Cantisán S; Agüera ML; Suñer M; Facundo C; Yuste JR; Fernández-Ruiz M; Montejo M; Redondo-Pachón D; López-Oliva MO; Fernández-Rodríguez A; Fariñas MC; Hernández D; Len O; Muñoz P; Valle-Arroyo J; Rodelo-Haad C; Cordero E; Torre-Cisneros J
J Infect Dis; 2021 Apr; 223(7):1205-1213. PubMed ID: 32779713
[TBL] [Abstract][Full Text] [Related]
64. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.
Giulieri S; Manuel O
Expert Rev Mol Diagn; 2011 Jan; 11(1):17-25. PubMed ID: 21171917
[TBL] [Abstract][Full Text] [Related]
65. Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli.
Gabanti E; Bruno F; Scaramuzzi L; Mangione F; Zelini P; Gerna G; Lilleri D
New Microbiol; 2016 Oct; 39(4):247-258. PubMed ID: 27727404
[TBL] [Abstract][Full Text] [Related]
66. Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors.
Schachtner T; Stein M; Reinke P
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28296035
[TBL] [Abstract][Full Text] [Related]
67. The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation.
Stranavova L; Hruba P; Girmanova E; Tycova I; Slavcev A; Fronek J; Slatinska J; Reinke P; Volk HD; Viklicky O
Physiol Res; 2018 May; 67(2):251-260. PubMed ID: 29303612
[TBL] [Abstract][Full Text] [Related]
68. QuantiFERON-CMV as a Predictor of CMV Events During Preemptive Therapy in CMV-seropositive Kidney Transplant Recipients.
Reusing JO; Agena F; Kotton CN; Campana G; Pierrotti LC; David-Neto E
Transplantation; 2024 Apr; 108(4):985-995. PubMed ID: 37990351
[TBL] [Abstract][Full Text] [Related]
69. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
Schlott F; Steubl D; Hoffmann D; Matevossian E; Lutz J; Heemann U; Hösel V; Busch DH; Renders L; Neuenhahn M
PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
[TBL] [Abstract][Full Text] [Related]
70. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
71. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
Kumar D; Chernenko S; Moussa G; Cobos I; Manuel O; Preiksaitis J; Venkataraman S; Humar A
Am J Transplant; 2009 May; 9(5):1214-22. PubMed ID: 19422346
[TBL] [Abstract][Full Text] [Related]
72. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
[TBL] [Abstract][Full Text] [Related]
73. Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients.
Jung J; Lee HJ; Kim SM; Kang YA; Lee YS; Chong YP; Sung H; Lee SO; Choi SH; Kim YS; Woo JH; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Virol; 2017 Feb; 87():5-11. PubMed ID: 27984766
[TBL] [Abstract][Full Text] [Related]
74. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
75. Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: A PRISMA-compliant article.
Ruan Y; Guo W; Liang S; Xu Z; Niu T
Medicine (Baltimore); 2019 Apr; 98(16):e15228. PubMed ID: 31008952
[TBL] [Abstract][Full Text] [Related]
76. ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients.
Zavaglio F; Rivela F; Cassaniti I; Arena F; Gabanti E; Asti AL; Lilleri D; Rampino T; Baldanti F; Gregorini M
J Med Virol; 2023 Feb; 95(2):e28507. PubMed ID: 36655741
[TBL] [Abstract][Full Text] [Related]
77. Cytomegalovirus Immunity Assays Predict Viremia but not Replication Within the Lung Allograft.
Li J; Gardiner BJ; Stankovic S; Oates CVL; Cristiano Y; Levvey BJ; Brooks AG; Snell GI; Westall GP; Sullivan LC
Transplant Direct; 2023 Jul; 9(7):e1501. PubMed ID: 37313314
[TBL] [Abstract][Full Text] [Related]
78. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
79. QuantiFERON-CMV assay by chemiluminescence immunoassay: Is it more suitable for real-live monitoring of transplant patients?
Fernández-Moreno R; Páez-Vega A; Rodríguez-Cano D; Salinas A; Rodríguez-Cantalejo F; Jurado A; Torre-Cisneros J; Cantisán S
J Clin Virol; 2024 Apr; 171():105651. PubMed ID: 38346360
[TBL] [Abstract][Full Text] [Related]
80. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
